$66.98 -$1.54 (0.0%)

03:38 PM EDT on 05/23/19

Repligen Corp (NASDAQ:RGEN)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.

Current Price $66.98 Mkt Cap $3.3B
Open $68.08 P/E Ratio 0.00
Prev. Close $66.98 Div. (Yield) $0.00 (0.0%)
Daily Range $66.26 - $68.08 Volume 56,152
52-Wk Range $49.07 - $71.07 Avg. Daily Vol. 6

Caps

How do you think NASDAQ:RGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

447 Outperform
11 Underperform
 

All-Star Players

85 Outperform
5 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:RGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBlacknGold (91.40)
Submitted April 11, 2016

I uncovered Repligen in 2013 when it was trading at a lowly $10 per share. At that time few had realized it was no longer developing drug candidates (risky, expensive, time-consuming -- apparently the TMF description for the company has yet to… More

Skyshadow664 (< 20)
Submitted June 14, 2012

These medical corporations tend to have spurts of large growth with long periods of notable decline. Just as Genetic Technologies as been fluctuating over the past year (a range from ~$2.50 - ~$10.00), this company follows a very similar trend. It… More

NASDAQ:RGEN VS S&P 500 (SPY)

Fools bullish on NASDAQ:RGEN are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about RGEN.

Recs

0
Member Avatar urmoney (99.39) Submitted: 6/28/2017 1:57:41 PM : Outperform Start Price: $41.59 NASDAQ:RGEN Score: +45.21

trend is your friend, buying the pullback

Recs

3
Member Avatar TMFBlacknGold (91.40) Submitted: 4/11/2016 1:12:57 PM : Outperform Start Price: $25.87 NASDAQ:RGEN Score: +117.37

I uncovered Repligen in 2013 when it was trading at a lowly $10 per share. At that time few had realized it was no longer developing drug candidates (risky, expensive, time-consuming -- apparently the TMF description for the company has yet to update) and instead focusing on supplying biologics manufacturers in the biopharma industry. And, of course, as a bioprocess engineer myself I'm biased towards bioprocessing companies. Duh.

I made a few hundred points and ended my original pick near $30 per share. Now I'm back in at $25 per share. Do I think this is really worth almost $1 billion? You could argue not, but I'm not betting against the high-margin growth prospects ahead, the cash-generation machine underpinning that growth, or management that loves to snatch up complimentary technologies through acquisitions and then integrate those products to boost growth. That generates more cash, which can then be used for more and/or bigger acquisitions, and the cycle continues. Nearly every product now sold by Repligen has been introduced through an acquisition, and management is showing no signs of laying off the trigger anytime soon.

In short, there's plenty of room to grow market share in its primary markets (which are also growing). Repligen may get punished when the broader biotech industry gets slapped on the wrist from time to time, but I like the long term prospects for the business. And remember, I'm biased.

Recs

0
Member Avatar SteveInFla (< 20) Submitted: 5/17/2015 3:12:40 PM : Outperform Start Price: $41.68 NASDAQ:RGEN Score: +27.73

I am confident that Repligen (RGEN) will do very well considering their significantly specific product(s) / ingredients that they produce for the companies that make up some of the worlds most vital anti-cancer medications such as Protein A", Being in the medical / research . biomedical field myself I can attest to this first hand. The fact that they have inked long term agreements with some of the largest manufacturers and subsequently their biomedical arms of their companies producing such "major" medications such as Herceptin, once and still in some circles considered the "miracle" treatment for multiple forms of Invasive Breast Ductal Carcinoma, Avastin and Humira for Rheumatoid arthritis speakd for itself. After all you can't make the cake without the flour, eggs and water....

Leaderboard

Find the members with the highest scoring picks in RGEN.

Score Leader

Stevegoldenfool

Stevegoldenfool (< 20) Score: +1,833.89

The Score Leader is the player with the highest score across all their picks in RGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Stevegoldenfool < 20 9/26/2011 Outperform 5Y $3.22 +1,980.12% +146.24% +1,833.89 0 Comment
TXawlman 94.11 10/26/2006 Outperform 5Y $3.37 +1,888.13% +116.35% +1,771.77 1 Comment
toroandbruin 54.38 10/25/2006 Outperform 1Y $3.37 +1,887.54% +116.61% +1,770.93 0 Comment
sincroton < 20 8/25/2006 Outperform 1Y $3.36 +1,893.45% +132.18% +1,761.27 1 Comment
warbucks52 < 20 8/25/2006 Outperform 1Y $3.36 +1,893.45% +132.30% +1,761.16 0 Comment
runic42 85.82 10/2/2006 Outperform 1Y $3.40 +1,870.00% +124.35% +1,745.65 0 Comment
Vanter1 99.42 11/11/2011 Outperform 5Y $3.41 +1,864.22% +122.65% +1,741.57 0 Comment
wonderpiks 51.33 5/6/2010 Outperform 5Y $3.42 +1,858.48% +142.74% +1,715.74 0 Comment
bigbob108 < 20 4/30/2007 Outperform NS $3.54 +1,792.09% +99.38% +1,692.71 0 Comment
Groovatorium 44.44 9/13/2010 Outperform 1Y $3.45 +1,841.45% +150.68% +1,690.77 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackmerriman 69.48 6/30/2009 Outperform NS $5.21 +1,185.60% +205.83% +979.77 0 Comment
TrackRodmanRen < 20 4/12/2007 Outperform NS $3.52 -2.55% -9.02% +6.47 3/7/2011 @ $3.43 0 Comment

Advertisement